Medicaid buy-in proposal would raise payment rates to match Medicare

U.S. Sen. Brian Schatz, D-Hawaii, is preparing to introduce legislation to allow Affordable Care Act (ACA) exchange customers to buy into Medicaid, offering a government-run “public option” similar to ones discussed but ultimately left out of the law.

In an interview with Vox, Schatz said if states take up the option, customers who qualify for ACA subsidies would be able to use them to buy into Medicaid. It would also raise Medicaid reimbursements for physicians and hospital to match that of Medicare to keep providers from turning away Medicaid patients, which he acknowledged would make the public option and Medicaid itself more expensive.

“You pay providers more; that doesn’t come from thin air,” Schatz said. “My judgment is you’re going to get better uptake if you have a broader provider network, and the more participants, the better the risk pool and the better the score.”

Democrats, like Republicans, have their own intraparty battles over healthcare policy, with 60 percent of the party’s members in the House signing onto a bill to introduce a single-payer system in the U.S. Schatz said he’s in favor of single-payer even as he crafts a different proposal which may not achieve universal coverage.

“If there’s ever a vote for single-payer, I’m a ‘yes,’” he told Vox. “But there are lots of things we can do in the meantime to make progress for tens of millions of Americans. And we should do those things.”

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.